Hem › Plasmacellscancer › Massachusetts › Boston
Kliniska studier för Plasmacellscancer i Boston, MA
5 studier för Plasmacellscancer söker deltagare vid platser i och runt Boston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RekryterarFas 3
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekryterarFas 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
RekryterarFas 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RekryterarFas 1/2
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
Rekryterar
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Plasmacellscancer-studier i andra städer
- Houston, TX5 studier
- New York City, NY4 studier
- Atlanta, GA4 studier
- Miami, FL3 studier
- Durham, NC3 studier
Andra studier i Boston
- Bröstcancer111 studier
- Icke-småcellig lungcancer90 studier
- Cancer (alla typer)86 studier
- Kolorektal cancer63 studier
- Metastaserande cancer63 studier
- Lungcancer62 studier
- Äggstockscancer61 studier
- Prostatacancer59 studier
- Depression52 studier
- Endometriecancer50 studier
- Hjärtsvikt44 studier
- Akut myeloid leukemi44 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.